The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer

被引:0
作者
Jun Liang
Tao Jiang
Ru-yong Yao
Zi-min Liu
Hong-ying Lv
Wei-wei Qi
机构
[1] Qing Dao University,Department of Oncology, The Affiliated Hospital of Medical College
[2] Qing Dao University,Central Laboratory, The Affiliated Hospital of Medical College
来源
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词
Metastatic colorectal cancer; XRCC1; ERCC1; Polymorphism; Oxaliplatin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:493 / 500
页数:7
相关论文
共 111 条
[1]  
Weitz J(2005)Colorectal cancer Lancet 365 153-165
[2]  
Koch M(1999)Colorectal cancer Lancet 353 391-399
[3]  
Debus J(2004)New options and old dilemmas in the treatment of patients with advanced colorectal cancer Ann Oncol 15 1453-1459
[4]  
Hohler T(2000)Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938-2947
[5]  
Galle PR(2005)Systemic therapy for metastatic colorectal cancer: current options, current evidence J Clin Oncol 23 4553-4560
[6]  
Buchler MW(1998)Oxaliplatin: a review of preclinical and clinical studies Ann Oncol 9 1053-1071
[7]  
Midgley R(2002)Cellular and molecular pharmacology of oxaliplatin Mol Cancer Ther 1 227-235
[8]  
Kerr D(2007)Platinum resistance related to a functional NER pathway J Thorac Oncol 2 1063-1066
[9]  
Punt CJ(2007)Current status of excision repair cross complementing-group 1 (ERCC1) in cancer Cancer Treat Rev 33 565-577
[10]  
De Gramont A(2003)The base excision repair: mechanisms and its relevance for cancer susceptibility Biochimie 85 1053-1071